AB

AllianceBernstein Holding L.P.

Congress Trades

NameValueActionAmount RangePriceCurrent Price
Nancy PelosiDemocrat
$3.0M
BuyJan 16, 2026
$1M-$5M
--
--
Nancy PelosiDemocrat
$3.0M
BuyJan 16, 2026
$1M-$5M
--
--
Nancy PelosiDemocrat
$3.0M
BuyJan 16, 2026
$1M-$5M
--
--
Nancy PelosiDemocrat
$3.0M
BuyJan 16, 2026
$1M-$5M
--
--

Insider Trades

NameValueActionPriceCurrent Price
Bernstein Seth PDirector, Officer: CEO
$1.1M29k shares
SellApr 30, 2026
$39.54
--
Bernstein Seth PDirector, Officer: CEO
$1.1M26.8k shares
SellFeb 18, 2026
$41.08
--
Bernstein Seth PDirector, Officer: President And CEO
$999k24.9k shares
SellAug 22, 2025
$40.05
--
Bernstein Seth PDirector, Officer: President And CEO
$19k480 shares
SellAug 20, 2025
$40.00
--
Bernstein Seth PDirector, Officer: President And CEO
$252k6.3k shares
SellAug 19, 2025
$40.13
--
Kaye Daniel GDirector
$197k4.8k shares
SellMay 12, 2025
$40.80
--

News

247wallst.comForget Big Tech: Nancy Pelosi Just Poured Millions Into This Under-the-Radar Dividend Stock247wallst.comJun 18globenewswire.comAB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilitiesglobenewswire.comJun 18globenewswire.comAB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042globenewswire.comJun 17globenewswire.comLe brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042globenewswire.comJun 17globenewswire.comAB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042globenewswire.comJun 17